Biomarker discovery lies at the heart of the translational gap in drug development. Too often, programs stall, and compounds fail in late-stage trials. Retrospective analyses repeatedly point to the same issue, a lack of mechanistic insight into the underlying biology during preclinical research.
AI is changing this not by merely speeding up existing workflows, but by unlocking new layers of biological understanding before a compound ever reaches human testing. Preclinical workflows are enhanced by AI integration, supporting more efficient and effective target validation.
The implications are profound. Approximately 90% of drug candidates entering clinical trials fail to gain regulatory approval, with lack of clinical efficacy accounting for the largest share of these failures. Identifying more predictive and translationally robust biomarkers earlier represents one of the highest-value opportunities for pharmaceutical R&D.
The Shortcomings of Traditional Biomarker Approaches
Traditional biomarker discovery workflows struggle to keep pace with the biological complexity of modern drug discovery. Relying on single-analyte approaches, sequential experiments, and siloed datasets, these methods yield insights that are narrow and often superficial.
Biomarkers derived from single-omic datasets frequently miss the systemic changes driving disease. Worse, they blur the line between cause and effect. Since these biomarkers emerge from isolated preclinical models, they often break down when tested in diverse patient populations typically seen in clinical trials.
In short, the signals guiding preclinical decisions rarely align with the biological factors that determine clinical outcomes.
AI-Enabled Multiomics: From Data to Mechanistic Insight
Over the past decade, multiomics (the simultaneous analysis of genomic, transcriptomic, proteomic, metabolomic, and epigenomic data) has produced unprecedented volumes of data. Yet the real challenge has been making sense of it all. In other words, turning these complex datasets into clear, actionable insights fast enough to guide early-stage drug discovery.
This is where AI comes into its own, particularly deep learning and graph neural networks (GNNs). Unlike traditional statistics, these models excavate non-linear relationships across data layers, revealing connections that would otherwise remain hidden. For instance, combining transcriptomic and proteomic data can uncover regulatory mechanisms that neither dataset alone could identify. Adding metabolomic and epigenomic layers then sheds light on the downstream functional impacts of those mechanisms.
Multimodal deep learning data fusion substantially improves cancer biomarker discovery compared with single-modality approaches. Combining AI with multiomics accelerates target identification, streamlines biomarker qualification, and improves the precision of clinical trial design.
In practical terms, this capability allows research teams to move beyond merely cataloguing differences between disease and control conditions. Instead, they can characterize which molecular signatures are truly driving a phenotype of interest. Biomarkers derived from this approach are far more likely to retain predictive validity across model systems and patient populations.
This distinction matters. A biomarker that reflects a downstream consequence of disease, rather than its mechanistic basis, will not reliably stratify patients, predict pharmacodynamic response, or meet the evidentiary standards required for regulatory acceptance as a clinical endpoint.
Bridging Preclinical and Clinical Data
The most transformative impact of AI may not lie in preclinical research itself, but in how it bridges the gap between preclinical and clinical data—two domains that have long operated in silos.
For years, preclinical drug discovery teams developed hypotheses, while clinical teams tested them. Critically, lessons from late-stage failures rarely made their way back to inform earlier research. The result? The same blind spots have plagued program after program, wasting resources and delaying treatments for patients.
Now, AI platforms are breaking this cycle. By integrating real-world clinical data—such as electronic health records, biobank cohorts, and historical trial results—into preclinical workflows, these tools enable researchers to validate hypotheses against real patient outcomes before committing to lengthy studies.
Natural language processing (NLP) models can extract mechanistic insights from decades of published clinical literature at a scale that no manual review could match. Federated learning allows models to be trained collaboratively across distributed clinical datasets without centralizing raw patient data, expanding applicability while preserving data governance compliance. Transfer learning techniques even allow models trained on human disease cohorts to inform the prioritization of preclinical endpoints before experiments begin.
The operational impact is significant: preclinical teams can now assess whether a proposed biomarker captures signals observed in clinically characterized patient populations before investing in a target, a model system, or a multi-year development strategy. Clinical intelligence, once available only retrospectively, is now a prospective input to early-stage decision-making.
Speeding Up Biomarker Qualification
AI is also accelerating biomarker qualification in several key ways.
Predictive models that are trained on historical data from preclinical-to-clinical transitions can red-flag biomarker candidates with poor track records. By assessing molecular class, target biology, and model system traits, these tools help teams drop weak candidates earlier, saving time and resources. Meanwhile, causal inference frameworks separate the wheat from the chaff, distinguishing biomarkers that drive disease from those that are merely byproducts which is a critical distinction for regulatory acceptance. Survival analysis models can even predict which early preclinical signals best indicate long-term clinical success, strengthening go/no-go decisions at the IND-enabling stage.
Importantly, these tools enhance experiments rather than replacing them. By focusing lab work on the most promising hypotheses, they sharpen decision-making and direct resources more effectively.
Strategic Implications for Pharmaceutical R&D
Companies that embrace AI-driven multiomics and clinical data integration in their preclinical workflows gain a clear edge: they validate targets faster, prioritize assets with stronger evidence, and build more robust biomarker packages for IND filings.
The translational gap in drug development largely stems from an inability to connect the dots. The data needed to improve preclinical decisions already exists, scattered across omics datasets, clinical records, biobanks, and the scientific literature. The real challenge has been making sense of it all quickly and accurately.
AI removes this bottleneck. For organizations that invest in the right platforms, infrastructure, and expertise, the payoff is not just incremental. It is a fundamentally more reliable path from preclinical insights to clinical success. Ultimately, this pushes faster access to life-changing medicines for patients.
References
- Amorim AMB, et al. Advancing Drug Safety in Drug Development: Bridging Computational Predictions for Enhanced Toxicity Prediction. Chem Res Toxicol. 2024;37(6):827–849. doi:10.1021/acs.chemrestox.3c00352
- Citeline/Norstella. Clinical Development Success Rates 2014–2023. 2024. Available at: norstella.com
- Ocana A, et al. Integrating AI in drug discovery and early drug development: a transformative approach. Biomark Res. 2025;13:45. doi:10.1186/s40364-025-00758-2
- Catacutan DB, Alexander J, Arnold A, Stokes JM. Machine learning in preclinical drug discovery. Nat Chem Biol. 2024;20:960–973.
- Athieniti E, Spyrou GM. A guide to multi-omics data collection and integration for translational medicine. Comput Struct Biotechnol J. 2023;21:134–149.
- Steyaert S, et al. Multimodal data fusion for cancer biomarker discovery with deep learning. Nat Mach Intell. 2023;5:351–362.
- Zhang et al. Multi-omics and AI for precision drug discovery and potential clinical applications. Signal Transduct Target Ther. 2026. doi:10.1038/s41392-026-02631-6
- Hanser T, Werner S, Plante J. Data-driven federated learning in drug discovery with knowledge distillation. Nat Mach Intell. 2025. doi:10.1038/s42256-025-00991-2
